PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-4889
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations ; volume:9 ; number:2 ; day:19 ; month:1 ; year:2018 ; pages:1-15 ; date:2.2018
Cell death & disease ; 9, Heft 2 (19.1.2018), 1-15, 2.2018
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
di Blasio, Laura
- Beteiligte Personen und Organisationen
-
Puliafito, Alberto
Gagliardi, Paolo Armando
Comunanza, Valentina
Somale, Desiana
Chiaverina, Giulia
Bussolino, Federico
Primo, Luca
SpringerLink (Online service)
- DOI
-
10.1038/s41419-017-0064-x
- URN
-
urn:nbn:de:1111-201804138591
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- di Blasio, Laura
- Puliafito, Alberto
- Gagliardi, Paolo Armando
- Comunanza, Valentina
- Somale, Desiana
- Chiaverina, Giulia
- Bussolino, Federico
- Primo, Luca
- SpringerLink (Online service)
Ähnliche Objekte (12)
PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations
PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
PIK3CA-mutations in breast cancer
Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations
PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma
PIK3CA mutations in endocrine-resistant breast cancer
Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations
PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
PIK3CA-mutations in breast cancer
Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations
PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma
PIK3CA mutations in endocrine-resistant breast cancer
Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations
PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
PIK3CA-mutations in breast cancer
Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations
PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma
PIK3CA mutations in endocrine-resistant breast cancer
Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations